SVRA: Savara Inc. Growth-Adjusted Market Cap to Net Income
Savara Inc. (SVRA) faces the risk of prolonged expenditures due to costly orphan drug development, yet its impeccable reputation within medical circles offsets these concerns. The PEG momentum indicator helps balance these factors, with the value of 0.00 reflecting the metric's most recent reading. Growth prospects are further bolstered by the anticipated FDA approval of molgramostim, positioning the company as an ideal acquisition target.
Metric breakdowns and analytics for Savara Inc. (SVRA)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
SVRA - Net Income|Expected Profit Savara Inc.|SVRA - P/E Multiple|Forward P/E Multiple Savara Pharma|SVRA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Savara Corp|SVRA - Operating profit EBITDA|Net earnings per share (EPS TTM) Savara|SVRA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months savarapharma.com|SVRA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Savara Inc.
General company analysis:SVRA - Savara Inc
To identify fundamentally resilient assets, investors utilize the PEG ratio, which correlates the current P/E multiple with net income growth rates, where a value below one signals that a company is undervalued. Analyzing the price-to-earnings-to-growth ratio for Savara Inc. (SVRA) allows for an assessment of the efficiency of its asset-light model and delegated manufacturing, determining the extent to which market value aligns with the development dynamics of its R&D projects.
Competitors of Savara Inc.
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|DNTH - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Pharvaris Pharma PHVS|ABCL: PEG Multiple|tourmalinebio.com (TRML) - PEG Multiple|Price/Earnings to Growth Multiple PGEN|Price/Earnings to Growth Ratio PHAR|PEG Multiple NKTR|PEG Multiple Upstream Pharma (UPB)|Price/Earnings to Growth Ratio Zenas Biopharma Inc ZBIO|Growth-Adjusted Payback Ratio IMNM|Gossamer Bio - PEG Multiple|KALV - PEG Multiple|SEPN (Septerna Corp) - Price/Earnings to Growth Multiple|Pieris Corp - Growth-Adjusted Payback Ratio|RIGL (Rigel Pharmaceuticals) - PEG Multiple|anaptysbio.com (ANAB) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Astria Therapeutics, Inc. (ATXS)|enGene Holdings Inc - Growth-Adjusted P/E Ratio|PEG Multiple RAPT (RAPT Therapeutics, Inc.)|JBIO - Price/Earnings to Growth Multiple|ACRS: Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income kyvernatx.com KYTX|Tiziana Life Sciences Ltd (TLSA) - Price/Earnings to Growth Ratio|CABA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple VTYX|Price/Earnings to Growth Ratio THTX|Price/Earnings to Growth Ratio Avalo Therapeutics, Inc (AVTX)|ELDN (eledon.com) - Growth-Adjusted Payback Ratio|PEG Multiple AGEN (Agenus Inc.)|PEG Multiple Climb Bio Inc. CLYM|ZURA - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio ATYR|ADAG: PEG Multiple|Ikena Oncology - Growth-Adjusted Payback Ratio|STTK (Shattuck Labs Inc) - PEG Multiple|PEG Multiple Equillium Bio|Price/Earnings to Growth Ratio Connect Biopharma (CNTB)|IMUX (immunic-therapeutics.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Atara Bio ATRA|IFRX - Price/Earnings to Growth Multiple|X4 Pharmaceuticals, Inc. - PEG Multiple|ACET - PEG Multiple|CELU (celularity.com) - Price/Earnings to Growth Multiple|INmune Bio Corporation - Growth-Adjusted Payback Ratio|BRNS (Barinthus Biotherapeutics) - PEG Multiple|kezarlifesciences.com (KZR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio SAB Biotherapeutics, Inc. (SABS)|Price/Earnings to Growth Multiple Akari Therapeutics PLC AKTX|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Price/Earnings to Growth Multiple|GOVX: Price/Earnings to Growth Multiple|EDSA - PEG Multiple|iBio (IBIO) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio CARM|XTLB (XTL Biopharmaceuticals, Ltd.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Bolt Bio BOLT|Price/Earnings to Growth Ratio HCW Biologics Inc. (HCWB)|Growth-Adjusted Market Cap to Net Income aptevotherapeutics.com|PEG Multiple AIM (AIM ImmunoTech)|PEG Multiple Aditxt Inc. ADTX|GRI: Price/Earnings to Growth Multiple|XRTX: Price/Earnings to Growth Ratio|HIND: PEG Multiple|revbiosciences.com (REVB) - PEG Multiple|Price/Earnings to Growth Ratio Indaptus Therapeutics, Inc.|SCNI: Growth-Adjusted Payback Ratio|PEG Multiple CALI|PEG Multiple affimed.com (AFMD)|Allakos - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio HOOK|IGM Bio - PEG Multiple|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics Inc ITOS|Ocean Bio (OCEA) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio TCBP|THRD (Third Harmonic Bio) - PEG Multiple
